US-China tensions threaten to ensnare additional Chinese biopharma contractors
04 Apr 2024
In recent weeks, proposed federal legislation has forced US drugmakers to rethink their relationship with a Chinese company that’s a staple in drug development. Now, the industry is starting to wake up to the potential for restrictions on additional Chinese biotech contractors.
The Biosecure Act threatens to blacklist WuXi AppTec and other “companies of concern” from doing business in the US. But less known is that the bill could expand to target additional Chinese firms, including contractors like Beijing-headquartered Pharmaron, which is the second-biggest contract research organization after WuXi; and synthetic DNA company GenScript, whose custom manufacturing services are based in Nanjing, China.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.